CoChat

A Two-Year Trial of Oleic and Erucic Acids (“Lorenzo's Oil”) as Treatment for Adrenomyeloneuropathy

Open access

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Adrenomyeloneuropathy is an X-linked recessive disorder characterized by myelopathy, peripheral neuropathy, and cerebral demyelination, which develop in association with the accumulation of very-long-chain fatty acids. The administration of oleic and erucic acids inhibits the synthesis of very-long-chain fatty acids. Recently such dietary treatment has been widely publicized as a possible cure for this disease. METHODS: We conducted an open trial in 14 men with adrenomyeloneuropathy, 5 symptomatic heterozygous women, and 5 boys (mean age, 13 years) with preclinical adrenomyeloneuropathy. The patients ate a low-fat diet and received daily doses of glycerol trioleate oil (1.7 g per kilogram of body weight) and glycerol trierucate oil (0.3 g per kilogram). Clinical manifestations, cerebral and spinal cord magnetic resonance imaging (MRI) scans, nerve conduction, and brain-stem auditory and somatosensory evoked potentials were studied prospectively over 18 to 48 months. Plasma levels of very-long-chain fatty acids and the side effects of erucic acid were monitored monthly. RESULTS: By week 10, plasma very-long-chain fatty acid levels declined nearly to normal. Nonetheless, over a mean follow-up of 33 months none of the 14 men with adrenomyeloneuropathy improved. In nine men there was functional deterioration, coincident in four with new cerebral lesions on MRI. In a single patient there was a reduction in cerebellar demyelination, but without clinical improvement. In one of the five asymptomatic boys signs of myelopathy developed. There were no changes in the symptomatic heterozygous women. There was some improvement in peroneal-nerve conduction, but no detectable clinical improvement. Conduction to the parietal cortex (T12-P37 interpeak latency) worsened in both the symptomatic men and the boys with preclinical adrenomyeloneuropathy. There was no change in other somatosensory evoked potentials or in brain-stem auditory evoked potentials. Asymptomatic thrombocytopenia (< 100,000 cells per cubic millimeter) was noted in six patients. CONCLUSIONS: In this open trial we found no evidence of a clinically relevant benefit from dietary treatment with oleic and erucic acids ("Lorenzo's oil") in patients with adrenomyeloneuropathy.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm199309093291101

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Research works printed but not linked: 7

  1. Moser HW, Moser AB. Adrenoleukodystrophy (X-linked). In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease. 6th ed. Vol. 2. New York: McGraw-Hill, 1989:1511-32.
  2. Brown FR, 1982, Johns Hopkins Med J, 151, 164
  3. Chazot G, 1979, Rev Neurol (Paris), 135, 211
  4. Duprey J, 1980, Ann Endocrinol (Paris), 41, 355
  5. Rondot P, 1984, Ann Med Interne (Paris), 135, 542
  6. Rouaud R, 1986, Rev Fr Endocrinol Clin, 27, 509
  7. Gastaut JL, 1988, Rev Neurol (Paris), 144, 338

Cited by

See all 243

Metadata

Authors
Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M.-C., Rocchiccioli, F., Cartier, N., Jambaque, I., Jakobezak, C., Lemaitre, A., Boureau, F., Wolf, C., & Bougneres, P.-F.
Affiliations
  • Inserm (FR)
  • Hôpital Saint-Vincent-de-Paul (FR)
  • Hôpital Saint-Antoine (FR)
Venue
New England Journal of Medicine
Published
1993-09-09
Volume
329
Issue
11
Pages
745-752
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2031484864
Cited by
242
References
43
Citations by year
2026: 3 · 2025: 3 · 2024: 3 · 2023: 7 · 2022: 15 · 2021: 6 · 2020: 5 · 2019: 7 · 2018: 5 · 2017: 5 · 2016: 9 · 2015: 7 · 2014: 7 · 2013: 8 · 2012: 6
FWCI
12.40
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
Keywords
adrenomyeloneuropathy, Lorenzo's oil, oleic acid, erucic acid, very long chain fatty acids, dietary therapy, X-linked recessive disorder, brain demyelination, myelopathy, nerve conduction, evoked potentials, thrombocytopenia
MeSH terms
Adolescent, Adrenoleukodystrophy, Adult, Brain, Child, Dietary Fats, Unsaturated, Drug Combinations, Electrophysiology, Erucic Acids, Fatty Acids, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Oleic Acids, Triolein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Two-Year Trial of Oleic and Erucic Acids (“Lorenzo's Oil”) as Treatment for Adrenomyeloneuropathy. https://app.cochat.ai/papers/10.1056/nejm199309093291101
The paper
Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M.-C., Rocchiccioli, F., Cartier, N., Jambaque, I., Jakobezak, C., Lemaitre, A., Boureau, F., Wolf, C., & Bougneres, P.-F. (1993). A Two-Year Trial of Oleic and Erucic Acids (“Lorenzo's Oil”) as Treatment for Adrenomyeloneuropathy. New England Journal of Medicine. https://doi.org/10.1056/nejm199309093291101

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.